Seattle, Washington (March 08, 2012) - ICAP at Columbia University’s Mailman School of Public Health is part of a network of research organizations that jointly released study results finding that the HIV infection rate of black women living in certain parts of the U.S. is five times higher than overall rate of infection among black women estimated by the Centers for Disease Control and Prevention (CDC).
The HIV Prevention Trials Network’s (HPTN) 064 Women’s HIV Seroincidence Study (ISIS) found an HIV incidence of 0.24% in its study cohort of 2,099 women (88% black).
Results are based on a study design that selected HIV ‘hot spots,’ i.e. geographic areas of the U.S. with elevated rates of HIV and poverty. Six distinct geographical areas in the northeast and southeast regions of the U.S. were selected—Atlanta, GA, Raleigh-Durham, NC, Washington D.C., Baltimore, MD, Newark, NJ, and New York City —where women, ages 18 to 44, without a prior positive HIV test were eligible for enrollment.
Within ICAP’s consortium of clinical research sites, the HPTN 064 study was conducted at three New York City-area sites: ICAP’s Harlem Prevention Center, the Bronx-Lebanon Hospital Center, and the New Jersey Medical School Adult Clinical Research Center. Investigators for the study included Drs. Wafaa El-Sadr, ICAP Director; Jessica Justman, ICAP Senior Technical Director; Sharon Mannheimer, Chief of Infectious Diseases at Harlem Hospital Center; Edward Telzak, Chief of Infectious Diseases/Director of AIDS Program at Bronx-Lebanon Hospital Center; and Sally Hodder, Vice Chair, Department of Medicine and Director, HIV/AIDS Program in the Division of Infectious Diseases at UMDNJ.
“This study confirms that black women in these U.S. hotspots have disproportionately been affected by HIV. While we have made significant progress in HIV/AIDS prevention, care, and treatment, our way forward must include prevention efforts tailored for these communities that are severely affected,” said Dr. El-Sadr, who is also professor of Epidemiology at Columbia’s Mailman School of Public Health and professor of Medicine at the College of Physicians and Surgeons.
Women constitute roughly one-quarter of new HIV infections in the U.S. with 66% of these infections occurring among black women, despite the fact that black women constitute only 14% of the U.S. female population. In the U.S., the age-adjusted death rate of black women with HIV is roughly 15 times higher than that observed for HIV-infected white women.
Thirty-two women in the study (1.5%) were newly diagnosed with HIV infection, at the time of enrollment, demonstrating the need to focus efforts on expanding HIV prevention and testing in hot spot areas of the US. “The study underscores the substantial ongoing HIV transmission within specific U.S. populations and highlights the need for increased focus on areas with higher HIV prevalence,” said Dr. Justman, who is also associate professor of clinical epidemiology at the Mailman School.
The HPTN 064 (ISIS) study is funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health. Study participants were enrolled between March 2008 and July 2010.
The NIH grant number is 5UM1Ai069466.
About ICAP
ICAP at Columbia University's Mailman School of Public Health is a global leader in public health, with a broad portfolio of research, training, health system strengthening, and service delivery programs in the United States and around the world. Founded in 2004, ICAP is committed to addressing critical health issues and to bettering lives by improving access to high-quality, equitable, and affordable health services. Working hand-in-hand with in-country partners, ICAP has supported more than 1,200 health facilities across 21 countries, including the US. More than one million people have received HIV services through ICAP-supported programs. For more information about ICAP, visit http://www.columbia-icap.org.
About the HIV Prevention Trials Network
The HIV Prevention Trials Network (HPTN) is a worldwide collaborative clinical trials network that develops and tests the safety and efficacy of primarily non-vaccine interventions designed to prevent the acquisition and transmission of HIV. The HPTN research agenda is focused primarily on reduction of HIV transmission and acquisition through the use of ART for HIV-infected persons and ARVs as pre-exposure prophylaxis (PrEP) for HIV-negative persons for HIV prevention, reducing the impact of behavioral and biologic co-factors that increase risk of infection, treatment of substance use (particularly injection drug use), behavioral risk reduction interventions, and structural interventions. The highest priority of the HPTN is to develop and implement combination prevention strategies that demonstrate a significant and measurable reduction in HIV incidence in a variety of populations and epidemic settings.